Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GEM-based hydrogel is a preclinical-stage therapeutic candidate developed by GEM-Biosciences, utilizing the company's proprietary Gas-Entrapping Materials (GEM) technology platform. This platform is designed to entrap and stabilize therapeutic gases, such as carbon monoxide (CO), within a material for localized delivery. The hydrogel formulation is intended for topical application to treat chronic and acute wounds, including diabetic foot ulcers, venous leg ulcers, and burns. By delivering CO directly to the wound site, the treatment aims to leverage the gas's anti-inflammatory, anti-apoptotic, and pro-angiogenic properties to facilitate tissue repair and accelerate healing. The GEM technology allows for the delivery of CO at concentrations that would be difficult to achieve systemically without toxicity, providing a targeted approach to gas therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on GEM-based hydrogel.